{"nctId":"NCT05087030","briefTitle":"Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis","startDateStruct":{"date":"2021-09-21","type":"ACTUAL"},"conditions":["Postmenopausal Osteoporosis"],"count":473,"armGroups":[{"label":"RGB-14-P (Main period)","type":"EXPERIMENTAL","interventionNames":["Drug: RGB-14-P"]},{"label":"Prolia® (Main period)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prolia®"]},{"label":"RGB-14-P (Transition period)","type":"EXPERIMENTAL","interventionNames":["Drug: RGB-14-P"]},{"label":"Prolia® (Transition period)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Prolia®"]},{"label":"RGB-14-P (Continued till transition period)","type":"EXPERIMENTAL","interventionNames":["Drug: RGB-14-P"]}],"interventions":[{"name":"RGB-14-P","otherNames":[]},{"name":"Prolia®","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant is an ambulatory postmenopausal woman, diagnosed with osteoporosis, able to walk, and not bedridden\n* Participant has an absolute BMD consistent with T score ≤ 2.5 and ≥ 4.0 at the lumbar spine as measured by dual-energy X-ray absorptiometry (DXA) during the Screening Period and at least 2 lumbar vertebrae (from L1 to L4) must be evaluable by DXA\n* Participant has body weight ≥ 50 and ≤ 90 kg at the Screening Period\n\nParticipants must meet the following criteria to be enrolled in the Transition Period:\n\n\\- Have been enrolled, received both doses of the test drug, and completed the scheduled Main Period (up to Week 52) of the RGB-14-101 study\n\nExclusion Criteria:\n\n* Participant has a history and/or presence of a severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray during the Screening Period\n* Participant has a history and/or presence of hip fracture\n* Participant has a history and/or presence of atypical femur fracture\n* Participant presents with an active healing fracture\n* Participant has a bilateral hip replacement (unilateral is allowed if the other hip is evaluable with DXA)\n* Participant has a vitamin D deficiency\n* Participant has hypocalcaemia or hypercalcemia at the Screening Period\n* Participant has a history and/or presence of bone metastases, renal osteodystrophy, osteomyelitis, any metabolic, endocrine or traumatic bone disease\n* Participant has a current uncontrolled status of hypothyroidism or hyperthyroidism\n* Participant has a history (within 5 years prior to Screening) and/or current hypoparathyroidism or hyperparathyroidism\n* Participant has malignancy within 5 years before Screening\n* Participant has a history and/or presence of significant cardiac disease\n* Participant has a known intolerance or malabsorption of calcium or vitamin D supplements\n* Participant shows contraindications to denosumab therapy (e.g., hypocalcaemia), or calcium or vitamin D supplementation before starting test drug administration\n* Participant has a latex allergy\n* Participant has a history and/or presence of osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures\n* Participant has history and/or presence of osteonecrosis of the external auditory canal\n* Participant requiring ongoing use of any osteoporosis treatment\n* Participant has previously received denosumab or biosimilar denosumab\n* Participant has weight or girth measurements which may preclude accurate DXA measurements\n* Participant has an active infection, including, but not limited to severe acute respiratory syndrome coronavirus-2, hepatis B, hepatitis C and human immunodeficiency virus infections during the Screening Period","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"60 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD)","description":"Percentage change from baseline in lumbar bone BMD was assessed. BMD at the lumbar spine was measured by dual-energy x-ray absorptiometry (DXA). This outcome measure was assessed for main period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.68","spread":"3.535"},{"groupId":"OG001","value":"5.19","spread":"4.118"}]}]}]},{"type":"PRIMARY","title":"Area Under the Effective Curve (AUEC) After the First Dose Until Day 183 of %CfB in Serum Type I Collagen C-telopeptide (sCTX)","description":"The AUEC of %CfB in sCTX of RGB-14-P was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants was demonstrated with postmenopausal osteoporosis. This outcome measure was assessed for main period only.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14609.67","spread":"3142.086"},{"groupId":"OG001","value":"14134.86","spread":"7331.714"}]}]}]},{"type":"SECONDARY","title":"%CfB in Total Hip BMD","description":"%CfB in total hip BMD was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"2.659"},{"groupId":"OG001","value":"2.69","spread":"2.519"},{"groupId":"OG002","value":"2.46","spread":"2.712"},{"groupId":"OG003","value":"2.81","spread":"2.607"},{"groupId":"OG004","value":"3.35","spread":"2.559"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.42","spread":"2.916"},{"groupId":"OG001","value":"3.49","spread":"2.872"},{"groupId":"OG002","value":"3.03","spread":"3.103"},{"groupId":"OG003","value":"3.36","spread":"2.696"},{"groupId":"OG004","value":"4.21","spread":"3.452"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"4.24","spread":"3.381"},{"groupId":"OG003","value":"4.12","spread":"3.128"},{"groupId":"OG004","value":"4.95","spread":"3.849"}]}]}]},{"type":"SECONDARY","title":"%CfB in Lumbar Spine BMD","description":"%CfB in lumbar spine BMD was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":"3.747"},{"groupId":"OG001","value":"3.45","spread":"4.227"},{"groupId":"OG002","value":"3.98","spread":"3.185"},{"groupId":"OG003","value":"3.39","spread":"3.848"},{"groupId":"OG004","value":"3.68","spread":"4.979"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"7.03","spread":"3.828"},{"groupId":"OG003","value":"7.06","spread":"4.327"},{"groupId":"OG004","value":"7.09","spread":"4.240"}]}]}]},{"type":"SECONDARY","title":"%CfB in Femoral Neck BMD","description":"%CfB in femoral neck BMD was assessed by DXA.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.88","spread":"3.040"},{"groupId":"OG001","value":"1.94","spread":"3.610"},{"groupId":"OG002","value":"1.60","spread":"2.833"},{"groupId":"OG003","value":"2.21","spread":"3.296"},{"groupId":"OG004","value":"2.35","spread":"4.057"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":"3.687"},{"groupId":"OG001","value":"2.64","spread":"3.751"},{"groupId":"OG002","value":"1.95","spread":"3.621"},{"groupId":"OG003","value":"2.60","spread":"3.127"},{"groupId":"OG004","value":"3.24","spread":"4.549"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"3.08","spread":"4.259"},{"groupId":"OG003","value":"3.06","spread":"3.337"},{"groupId":"OG004","value":"4.04","spread":"4.764"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Vertebral Fragility Fracture","description":"Number of participants with vertebral fragility fracture was assessed. Information on vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"4","spread":null},{"groupId":"OG004","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Non-vertebral Fragility Fracture","description":"Number of participants with non-vertebral fragility fracture was assessed. Information on non-vertebral fractures was centrally collected through the evaluation of lateral thoraco-lumbar spine X-ray.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"%CfB in Serum Procollagen Type 1 N Terminal Propeptide (P1NP)","description":"%CfB in serum P1NP was assessed as part of pharmacodynamics parameter with US-licensed Prolia® in female participants with postmenopausal osteoporosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.10","spread":"14.905"},{"groupId":"OG001","value":"20.22","spread":"15.091"},{"groupId":"OG002","value":"19.85","spread":"13.939"},{"groupId":"OG003","value":"18.45","spread":"15.835"},{"groupId":"OG004","value":"17.31","spread":"15.524"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.92","spread":"17.828"},{"groupId":"OG001","value":"62.89","spread":"29.294"},{"groupId":"OG002","value":"68.42","spread":"11.693"},{"groupId":"OG003","value":"63.41","spread":"42.677"},{"groupId":"OG004","value":"66.08","spread":"16.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.04","spread":"19.131"},{"groupId":"OG001","value":"63.82","spread":"21.712"},{"groupId":"OG002","value":"64.86","spread":"16.902"},{"groupId":"OG003","value":"66.05","spread":"20.428"},{"groupId":"OG004","value":"65.89","spread":"17.651"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"64.12","spread":"18.845"},{"groupId":"OG003","value":"66.91","spread":"16.816"},{"groupId":"OG004","value":"63.08","spread":"21.364"}]}]}]},{"type":"SECONDARY","title":"%CfB in Serum Type I Collagen C-telopeptide (sCTX)","description":"%CfB in sCTX was assessed as part of pharmacodynamics parameter with US-licensed Prolia® was assessed in female participants with postmenopausal osteoporosis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.87","spread":"9.567"},{"groupId":"OG001","value":"85.38","spread":"15.501"},{"groupId":"OG002","value":"84.96","spread":"11.206"},{"groupId":"OG003","value":"84.71","spread":"23.071"},{"groupId":"OG004","value":"88.08","spread":"5.832"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.74","spread":"23.212"},{"groupId":"OG001","value":"61.51","spread":"83.764"},{"groupId":"OG002","value":"67.29","spread":"23.572"},{"groupId":"OG003","value":"53.23","spread":"147.679"},{"groupId":"OG004","value":"71.27","spread":"17.483"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.90","spread":"28.995"},{"groupId":"OG001","value":"58.26","spread":"63.927"},{"groupId":"OG002","value":"60.41","spread":"31.958"},{"groupId":"OG003","value":"53.89","spread":"94.853"},{"groupId":"OG004","value":"66.79","spread":"24.151"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"58.70","spread":"34.117"},{"groupId":"OG003","value":"53.32","spread":"42.855"},{"groupId":"OG004","value":"57.38","spread":"30.562"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"The safety and tolerability of RGB-14-P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"158","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"152","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"149","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"25","spread":null},{"groupId":"OG004","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-drug Antibodies (ADAs)","description":"Number of participants with positive ADAs was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neutralizing Antibodies","description":"Number of participants with positive neutralizing antibodies was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[]},{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[]}]},{"type":"SECONDARY","title":"Titre of ADAs","description":"The immunogenicity of RGB -14- P with US-licensed Prolia® in female participants with postmenopausal osteoporosis was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"302.0","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"761.0","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"172.0","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"172.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"211.0","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"211.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"224.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"152.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"NA","spread":null},{"groupId":"OG003","value":"NA","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":242},"commonTop":["Nasopharyngitis","Hypocalcaemia","COVID-19","Upper respiratory tract infection","Urinary tract infection"]}}}